Endpoints News – The biopharma world is here

SUBSCRIBE

top stories

Eyeing big therapeutic push, Ginkgo bags $290M to build a cell programming empire

20 hours ago

UPDATED: Speaker Nancy Pelosi to unveil bill for federally negotiated drug prices

20 hours ago

'Disconnect the bastards' — one biotech's plan to break cancer cells' unified defenses

Yesterday

Latest

Most read

A favorite in Alexion’s C-suite is leaving, and some mighty surprised analysts aren’t the least bit happy about ...

Yesterday

As Nasdaq enrolls the final batch of 2019 IPOs, how have the numbers compared to past years?

1 minute ago

Emmaus rescinds EU marketing application, following negative review

4 minutes ago

While Novartis banishes Zolgensma scandal scars — Biogen goes on a Spinraza 'offensive'

20 hours ago

see latest stream

People

Senators to FTC: Don't let the big Celgene and Allergan buyouts hurt R&D and consumers

Yesterday

Scott Gottlieb is once again joining a team that enjoyed good times at the FDA under his high-energy stint at the ...

2 days ago

Scott Gottlieb has a new board position to add to the resume — and this one is focused on a favorite subject

3 days ago

Startups

Jeff Kindler's Centrexion renews bid to make public debut

Yesterday

'A fourth revolution in cancer therapies': ARCH-backed Boundless Bio flashes big check, makes bigger promises in ...

Yesterday

Biotech boards burdened: Bridging the success gap

Yesterday

Deals

UPDATED: Deborah Dunsire is paying $2B for a chance to leap directly into a blockbuster showdown with a few of the ...

4 days ago

From partner to knight in shining armor: Castle Creek to buy Fibrocell

Last week

Another pharma giant makes a leap into the global medical marijuana business

Last week

IPOs

Chalk up a big win for Bain as SpringWorks IPO tops out at $162M

Last week

How about a $477M biotech IPO amid Hong Kong protests? Henlius will find out

Last week

Hong Kong strife holds up almost $100M of BioNTech's Series B haul

Last week

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW

Subscribe to Endpoints News

Premium storiesSee all

Vertex buys the top spot on the list of the biggest preclinical M&A deals. Were they robbed or was it a steal?

3 weeks ago

Worst. biotech. deal. ever? Turns out AbbVie has plenty of competition for that title

3 weeks ago

Webinar: Real World Endpoints — the brave new world coming in building franchise therapies

5 weeks ago

Bayer’s $240M upfront for BlueRock acquisition puts them in the high rollers club for preclinical biotech buyouts

Last month

Don't missSee all

Preclinical cancer biotech IGM Biosciences sets stage for upsized $175M IPO

2 days ago

San Diego couple charged with stealing trade secrets, opening Chinese biotech as DOJ crackdown continues

2 days ago

UPDATED: Biogen pulls the plug on prized IPF drug from $562M+ Stromedix buyout

2 days ago

It's not perfect, but it's a good start: FDA panelists largely endorse Aimmune's peanut allergy therapy

6 days ago

Peer review See all

Sep

13

Alex Arfaei trades his analyst's post for a new role as biotech VC; Sanofi vet heads to Vifor

Sep

6

Randy Schatzman jumps to the helm of another start-up; Novo Nordisk vet lands top post at Macrophage Pharma

Aug

30

Ex-Altimmune chief Bill Enright lands CEO role at Vaccitech; Reata poaches Alnylam CFO Manmeet Soni

Aug

23

Ignyta founder boosts team at his new cancer startup; Cytomx CMO hits the exit

Aug

16

Bain's Orly Mishan joins Pfizer's neuro spinout Cerevel; Oncolytic virus biotech taps SillaJen exec Helena Chaye as CEO

R&D channel feed

3 days ago

Warts for the win: Aclaris' lead drug clears pivotal study

Aclaris Therapeutics has found a way to get rid of the warts and all. The company — which earlier this month decided to focus on its arsenal of kinase inhibitors — on Monday unveiled ...

READ MORE

Could psychedelics tackle the obesity crisis? A longtime researcher in the field says his latest mouse study suggests ...

3 days ago

Acceleron drops a development program as #2 drug fails to spark functional benefits in patients with a rare ...

3 days ago

latest in R&D

Cancer trials aimed at 'surrogate' targets miss bigger mark — study

22 hours ago

Zolgensma didn't cause an infant death, AveXis execs say as they spotlight long-term data

23 hours ago

Young anti-aging field takes big step with Mayo Clinic senolytics showcase

Yesterday

Seattle Genetics/Astellas win priority US review for armed antibody aimed at bladder cancer

3 days ago

Karyopharm lines up $150 million cash injection to back controversial drug launch

3 days ago

see latest stories

Pharma channel feed

3 days ago

Purdue Pharma files for bankruptcy as first step in $10B opioid settlement

It’s settled. Purdue Pharma has filed for bankruptcy as part of a deal that would see the OxyContin maker hand over $10 billion in cash and other contributions to mitigate the opioid crisis ...

READ MORE

After touting Gazyva's potential in lupus, Roche nabs 'breakthrough' ahead of PhIII

Yesterday

Population pharmacokinetics: Drugmakers seek clarity and additions to revised FDA guidance

Yesterday

latest in Pharma

Vertex deal for Scotland — no deal for England

6 days ago

Roche's Tecentriq excels in another lung cancer study

Last week

Look out Alexion, Roche breaks out the details on its rival rare CNS drug

Last week

Indian manufacturing player Jubilant poaches top Novartis BD exec to run their new biotech startup in Yardley, PA

Last week

CDER chief Janet Woodcock has a message for pharma: 'It’s not working, and it won’t work in the future'

Last week

see latest stories